Alvotech priced 22.7 million shares at $3.75 each in a public offering expected to close June 17, generating gross proceeds of about $85 million plus a 3.4 million share option. Concurrently, it plans to sell 17.8 million shares in a private placement for roughly $67 million to fund biosimilar development.
Alvotech priced 22.7 million shares at $3.75 per share in a public offering and granted underwriters a 30-day option to purchase up to 3.4 million additional shares at the same price. The offering is expected to close on or about June 17, 2026, generating approximately $85 million in gross proceeds before fees, or up to $98 million if the overallotment option is fully exercised.
Simultaneously, the company entered into subscription agreements to sell 17.8 million ordinary shares at $3.75 per share in a private placement exempt from registration, anticipated to close on or about June 25, 2026, and expected to raise about $67 million in gross proceeds. The private placement is not contingent on the public offering’s completion but follows customary closing conditions.
Alvotech intends to use the net proceeds to advance its biosimilar pipeline—covering pre-clinical and clinical development, research and development, intellectual property protection, and pre-commercialization activities—as well as for working capital, capital expenditures, potential acquisitions or collaborations and repayment or refinancing of indebtedness.
